Biocon Limited — Important, 02-06-2025: General Updates

Biocon has announced a board meeting to approve the financial results for the quarter and half-year. Its subsidiary, Biocon Pharma, secured approval for generic Liraglutide in India, targeting Type 2 Diabetes patients aged 10 and above. This expands affordable GLP-1 treatment options in a large diabetes market of 77 million patients. Biocon plans to launch Liraglutide soon, positioning GLP-1 therapies as a major growth avenue.